The role of GH in cancer therapy resistance involves facilitating active drug efflux, induction of phenotypic plasticity via epithelial-to-mesenchymal transition (EMT), modulation of the tumor microenvironment (TME), and enabling evasion of apoptosis [19,26,28,29,30,34,35,38,39]. Here, GH1 is linked to cancer.